



Q U E S T C O R

Discontinuation of Inulin in Sodium Chloride Injection, USP

Dear Healthcare Provider:

As a result of a permanent shortage in drug substance, Questcor Pharmaceuticals, Inc. has decided to discontinue Inulin in Sodium Chloride Injection, USP.

Inulin in Sodium Chloride Injection, USP is indicated for the measurement of glomerular filtration rate.

Currently, several agents are available on the US market that can be used for the above-described indication, including GLOFIL®-125 (Sodium Iothalamate I-125 Injection, USP). Therefore, the discontinuation of Inulin in Sodium Chloride Injection, USP from the US market will have none or a minimal effect on patient care.

If you have a medical question regarding Inulin in Sodium Chloride Injection, USP, please feel free to call our Medical Affairs department at 1-800-411-3065.

We appreciate your understanding.

Sincerely,

Matthias C. Kurth, MD, PhD
VP, Medical and Regulatory Affairs